Champions weren't just basking in glory at the Sochi Winter Olympic games this week. The world of health care produced quite a few stocks deserving gold medals in their own way.
Breaking news about a big acquisition propelled one of our humongous health-care stocks higher this week. Accelerated approval from the U.S. Food and Drug Administration for a promising drug did the trick for another stock. And one huge winner's gains didn't have an obvious catalyst.
Which health-care stocks claimed the thrill of victory this week? Find out by watching the slideshow below.
Keith Speights owns shares of Actavis. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Anti-Depressants: The Secret to Preventing Alzheimer's?
Scientists are exploring the ways serotonin reuptake inhibitors might be able to slow Alzheimer's.
Why Did Forest Laboratories Buy Furiex Pharmaceuticals?
Forest Laboratories bought Furiex Pharmaceuticals. Smart move?
Why Furiex Pharmaceuticals Inc. Shares Skyrocketed
Furiex shares soar after agreeing to be purchased by Forest Labs. Find out if this is a smart move or wasted money on Forest Labs' part.